apparent for US patients C. Recommendations for adults with AS-related comorbidities In adults with AS and recurrent uveitis, we conditionally recommend treatment with TNFi monoclonal antibodies over treatment with other biologics (PICO 29). Evidence for this recommendation is limited to indirect comparisons of the rates of acute uveitis episodes in clinical trials or observational studies, rather than from direct comparisons (see Supplementary Appendix 6, available at http://onlin elibr